Sudden cardiac death in haemodialysis patients: Preventative options

Nephrology

Volumn 19, Issue 12, 2014, Pages 740-749

  Chiu, Diana Yuan Yng ^a,b   Sinha, Smeeta ^a,b   Kalra, Philip A ^a,b   Green, Darren ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

cardiac; death; dialysis; sudden; therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALLOPURINOL; ALPHA TOCOPHEROL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATENOLOL; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; OMEGA 3 FATTY ACID; PLACEBO; POTASSIUM; RECOMBINANT ENZYME; RECOMBINANT RENALASE; ROSUVASTATIN; SOTALOL; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CORONARY ARTERY BYPASS GRAFT; DIALYSATE; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG WITHDRAWAL; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG TOXICITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; RISK REDUCTION; SUDDEN CARDIAC DEATH; THYROID DISEASE; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CAUSE OF DEATH; COMPLICATION; DEATH, SUDDEN, CARDIAC; KIDNEY FAILURE, CHRONIC; MORTALITY; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT;

CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84936741481     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12337     Document Type: Article

References (67)

1. Avenue G,. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2006; 114: 1088-1132.
2. US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
3. Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP,. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int. 2011; 79: 218-227.
4. Nishimura M, Tokoro T, Nishida M, et al. Sympathetic overactivity and sudden cardiac death among hemodialysis patients with left ventricular hypertrophy. Int. J. Cardiol. 2010; 142 (1): 80-86.
5. Matsue Y, Suzuki M, Nagahori W, Ohno M, Matsumura A, Hashimoto Y,. Beta-blocker prevents sudden cardiac death in patients with hemodialysis. Int. J. Cardiol. 2011; 165: 519-522.
6. Jadoul M, Thumma J, Fuller D, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2012; 7: 765-774.
7. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2003; 41: 1438-1444.
8. Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG,. Hypertension in hemodialysis patients treated with atenolol or lisinopril: A randomized controlled trial. Nephrol. Dial. Transplant. 2014; 29: 672-681.
9. Miller LM, Hopman WM, Garland JS, Yeates KE, Pilkey RM,. Cardioprotective medication use in hemodialysis patients. Can. J. Cardiol. 2006; 22: 755-760.
10. Furgeson SB, Chonchol M,. Beta-blockade in chronic dialysis patients. Semin. Dial. 2008; 21: 43-48.
11. Myerburg R, Kessler K, Mallon S, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N. Engl. J. Med. 1992; 326: 1451-1455.
12. Pun PH, Lehrich RW, Smith SR, Middleton JP,. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol. 2007; 2: 491-500.
13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 1997; 336: 525-533.
14. Chan KE, Lazarus JM, Hakim RM,. Digoxin associates with mortality in ESRD. J. Am. Soc. Nephrol. 2010; 21: 1550-1559.
15. Piccini JP, Berger JS, O'Connor CM,. Amiodarone for the prevention of sudden cardiac death: A meta-analysis of randomized controlled trials. Eur. Heart J. 2009; 30: 1245-1253.
16. Shastri S, Tangri N, Tighiouart H, et al. Predictors of sudden cardiac death: A competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol. 2012; 7 (1): 123-130.
17. Kitano Y, Kasuga H, Watanabe M, et al. Severe coronary stenosis is an important factor for induction and lengthy persistence of ventricular arrythmias during and after hemodialysis. Am. J. Kidney Dis. 2004; 44: 328-336.
18. Green D, Ritchie JP, Kalra PA,. Meta-analysis of lipid-lowering therapy in maintenance dialysis patients. Nephron Clin. Pract. 2013; 124: 209-217.
19. Tung P, Van Denburgh M, Buring J, Gazino M, Manson J, Albert C,. Aspirin, vitamin E and risk of sudden cardiac death in healthy individuals. J. Am. Coll. Cardiol. 2013; 61: E1339.
20. Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2007; 50: 602-611.
21. Tomaschitz A, Pilz S, Ritz E, et al. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am. J. Kidney Dis. 2011; 57: 403-414.
22. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA,. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 1999; 33: 598-604.
23. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006; 70: 1318-1324.
24. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol. Dial. Transplant. 2006; 21: 2507-2512.
25. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
26. Chua D, Lo A, Lo C,. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: Is it safe? Clin. Cardiol. 2010; 33: 604-608.
27. Hammer F, Krane V, Störk S, et al. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transpl. 2014; 29: 400-405.
28. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur. Heart J. 2000; 21: 2071-2078.
29. National Institute for Health and Clinical Excellence (NICE). NICE guidance on cardiac resynchronisation therapy (CRT) and implantable cardioverter defibrillators (ICDs) [Internet]. 2006 [Cited 6 Feb 2014.] Available from URL: http://www.nice.org.uk/guidance/ta314
30. Dasgupta A, Montalvo J, Medendorp S, et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am. J. Kidney Dis. 2007; 49: 656-663.
31. Hager CS, Jain S, Blackwell J, Culp B, Song J, Chiles CD,. Effect of renal function on survival after implantable cardioverter defibrillator placement. Am. J. Cardiol. 2010; 106: 1297-1300.
32. Makki N, Swaminathan PD, Hanmer J, Olshansky B,. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. Europace 2014; 16: 55-62.
33. Sakhuja R, Keebler M, Lai T-S, McLaughlin Gavin C, Thakur R, Bhatt DL,. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am. J. Cardiol. 2009; 103: 735-741.
34. Hreybe H, Ezzeddine R, Bedi M, et al. Renal insufficiency predicts the time to first appropriate defibrillator shock. Am. Heart J. 2006; 151: 852-856.
35. Charytan D, Patrick A, Liu J, et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am. J. Kidney Dis. 2011; 58: 409-417.
36. Duray GZ, Schmitt J, Richter S, Israel CW, Hohnloser SH,. Arrhythmic death in implantable cardioverter defibrillator patients: A long-term study over a 10 year implantation period. Europace 2009; 11: 1462-1468.
37. Mangrum M, Lin D, Dimarco J, Lake D, Bolton K, Mangrum A,. Prognostic value of left ventricular systolic function in renal dialysis patients. Hear Rhythm. 2006; 3: s154.
38. De Bie MK, van Dam B, Gaasbeek A, et al. The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. Eur. Heart J. 2009; 30: 1559-1564.
39. Parfrey PS, Foley RN,. The clinical epidemiology of cardiac disease in chronic renal failure. J. Am. Soc. Nephrol. 1999; 10: 1606-1615.
40. Szummer K, Lundman P, Jacobson S, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction. Circulation 2009; 120: 851-858.
41. Herzog CA, Strief JW, Collins AJ, Gilbertson DT,. Cause-specific mortality of dialysis patients after coronary revascularization: Why don't dialysis patients have better survival after coronary intervention? Nephrol. Dial. Transplant. 2008; 23: 2629-2633.
42. Foley RN, Gilbertson DT, Murray T, Collins AJ,. Long interdialytic interval and mortality among patients receiving hemodialysis. N. Engl. J. Med. 2011; 365: 1099-1107.
43. Zhang H, Schaubel DE, Kalbfleisch JD, et al. Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-of-week mortality. Kidney Int. 2012; 81: 1108-1115.
44. Morrison G, Michelson EL, Brown S, Morganroth J,. Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int. 1980; 17: 811-819.
45. Genovesi S, Valsecchi MG, Rossi E, et al. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol. Dial. Transplant. 2009; 24: 2529-2536.
46. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2007; 2: 999-1007.
47. Karnik J, Young B, Lew N, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001; 60: 350-357.
48. Pun PH, Horton JR, Middleton JP,. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2013; 8: 797-803.
49. Ferrario M, Moissl U, Garzotto F, et al. Effects of fluid overload on heart rate variability in chronic kidney disease patients on hemodialysis. BMC Nephrol. 2014; 15 (1): 26.
50. Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis: A systematic review. Clin. J. Am. Soc. Nephrol. 2006; 1 (1): 33-42.
51. Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am. J. Kidney Dis. 2001; 38: 371-376.
52. Traeger J, Galland R, Delawari E, Arkouche W, Hadden R,. Six years' experience with short daily hemodialysis: Do the early improvements persist in the mid and long term? Hemodial. Int. 2004; 8: 151-158.
53. The FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N. Engl. J. Med. 2010; 363: 2287-2300.
54. Lacson E, Xu J, Suri RS, et al. Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J. Am. Soc. Nephrol. 2012; 23: 687-695.
55. Gissi-prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction?: Results of the GISSI-Prevenzione trial. Lancet 1999; 354 (9177): 447-455.
56. Singh R, Rastogi S, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: Results of one year follow-up. BMJ 1992; 304: 1015-1019.
57. Friedman AN, Yu Z, Tabbey R, et al. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int. 2013; 83: 1130-1135.
58. Mozaffarian D, Wu JHY,. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011; 58: 2047-2067.
59. Chen J, Shearer GC, Chen Q, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011; 123: 584-593.
60. Fischer R, Dechend R, Qadri F, et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 2008; 51: 540-546.
61. Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J. Am. Soc. Nephrol. 2011; 22: 1382-1389.
62. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J. Clin. Invest. 2005; 115: 1275-1280.
63. Dhalla NS, Adameova A, Kaur M,. Role of catecholamine oxidation in sudden cardiac death. Fundam. Clin. Pharmacol. 2010; 24: 539-546.
64. Wu Y, Xu J, Velazquez H, et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int. 2011; 79: 853-860.
65. Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: Survival in 415 patients treated for 1006 patient-years. Nephrol. Dial. Transplant. 2008; 23: 3283-3289.
66. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A,. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002; 61: 2235-2239.
67. Taddio A, Appleton M, Bortolussi R, et al. Reducing the pain of childhood vaccination: An evidence-based clinical practice guideline (summary). CMAJ 2010; 182: 1989-1995.